NASH Drug Developers 89Bio and ETNB See Promising Results in Mid-Stage Trials
89bio's Phase IIb data showed its drug, an analog of FGF21, was better than placebo at lessening fibrosis without worsening NASH in two of three dose groups. The data pave the way for a potential Phase III, following in the footsteps of another biotech in its drug class, Akero Therapeutics. To fund a late-stage study, 89bio "would need to raise additional capital," with the company having about $188 million at the end of last year.
